nach oben

Current Nutrition Reports

Erschienen in:

01.06.2015 | Neurological Disease and Cognitive Function (G Logroscino, Section Editor)

The Role of Copper in Human Diet and Risk of Dementia

verfasst von: Rosanna Squitti, Franca Tecchio, Mariacarla Ventriglia

Erschienen in: Current Nutrition Reports | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Alzheimer’s disease (AD) is one of the most devastating epidemics of the twenty-first century, and no cure is currently available. One third of all AD cases can be attributed to modifiable risk factors (such as physical inactivity, smoking, hypertension, diabetes, and obesity in middle age). Accordingly, seven nutritional and lifestyle guidelines for the prevention of AD have been proposed to the public. The present review addresses the fifth guideline, which focuses on the significance of the breakdown of copper homeostasis as a risk factor for AD. Dietary copper in the human diet, the physiological pathway of copper in the body, copper metabolic abnormalities in AD (as revealed by clinical studies and large population datasets), and the onset of copper metabolic abnormalities (as a result of the interplay between copper intake and genetic defects linked primarily to the ATP7B gene) are reported herein. Data are discussed in the framework of evidence-based medicine to guide decision-making in AD clinical practice and prevention towards the adoption of an adequate dietary copper regimen in susceptible individuals.

Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112–7. doi:10.1016/S0140-6736(05)67889-0.PubMedCentralPubMedCrossRef

2.••

Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788–94. doi:10.1016/S1474-4422(14)70136-X. This article presents the preventive potential of Alzheimer’s disease.PubMedCrossRef

3.••

Barnard ND, Bush AI, Ceccarelli A, Cooper J, de Jager CA, Erickson KI, et al. Dietary and lifestyle guidelines for the prevention of Alzheimer’s disease. Neurobiol Aging. 2014;35 Suppl 2:S74–8. doi:10.1016/j.neurobiolaging.2014.03.033. This article presents dietary and lifestyle guidelines for the Prevention of Alzheimer’s Disease.PubMedCrossRef

4.••

Pal A, Siotto M, Prasad R, Squitti R. Towards a unified vision of copper involvement in Alzheimer’s Disease: a review connecting basic, experimental, and clinical research. J Alzheimers Dis. 2014. This review discusses the coherence of diverse types of evidence of copper involvement in Alzheimer’s disease.

5.•

Squitti R, Siotto M, Polimanti R. Low-copper diet as a preventive strategy for Alzheimer’s disease. Neurobiol Aging. 2014;35 Suppl 2:S40–50. doi:10.1016/j.neurobiolaging.2014.02.031. This article presents data about copper involvement in Alzheimer’s disease from a nutritional perspective.PubMedCrossRef

Deveau M. Contribution of drinking water to dietary requirements of essential metals. J Toxic Environ Health A. 2010;73(2):235–41. doi:10.1080/15287390903340880.CrossRef

Ahmad Z, Pandey R, Sharma S, Khuller GK. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci. 2006;48(3):171–6.PubMed

Barrington JW, Lindsay P, James D, Smith S, Roberts A. Selenium deficiency and miscarriage: a possible link? Br J Obstet Gynaecol. 1996;103(2):130–2.PubMedCrossRef

Turnlund JR. Human whole-body copper metabolism. Am J Clin Nutr. 1998;67(5 Suppl):960S–4.PubMed

10.

Turnlund JR, Keyes WR, Anderson HL, Acord LL. Copper absorption and retention in young men at three levels of dietary copper by use of the stable isotope 65Cu. Am J Clin Nutr. 1989;49(5):870–8.PubMed

11.

Kaler SG. ATP7A-related copper transport diseases-emerging concepts and future trends. Nat Rev Neurol. 2011;7(1):15–29. doi:10.1038/nrneurol.2010.180.PubMedCentralPubMedCrossRef

12.

Kaler SG, Holmes CS, Goldstein DS, Tang J, Godwin SC, Donsante A, et al. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med. 2008;358(6):605–14. doi:10.1056/NEJMoa070613.PubMedCentralPubMedCrossRef

13.

Walshe JM. Wilson’s disease: the importance of measuring serum caeruloplasmin non-immunologically. Ann Clin Biochem. 2003;40(Pt 2):115–21. doi:10.1258/000456303763046021.PubMedCrossRef

14.

Fujiwara N, Iso H, Kitanaka N, Kitanaka J, Eguchi H, Ookawara T, et al. Effects of copper metabolism on neurological functions in Wistar and Wilson’s disease model rats. Biochem Biophys Res Commun. 2006;349(3):1079–86. doi:10.1016/j.bbrc.2006.08.139.PubMedCrossRef

15.

Morris MC, Evans DA, Tangney CC, Bienias JL, Schneider JA, Wilson RS, et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol. 2006;63(8):1085–8. doi:10.1001/archneur.63.8.1085.PubMedCrossRef

16.••

Mursu J, Robien K, Harnack LJ, Park K, Jacobs Jr DR. Dietary supplements and mortality rate in older women: the Iowa Women’s Health Study. Arch Intern Med. 2011;171(18):1625–33. doi:10.1001/archinternmed.2011.445. This article presents data of supplements effects on the rate of mortality.PubMedCentralPubMedCrossRef

17.

Georgopoulos PG, Roy A, Yonone-Lioy MJ, Opiekun RE, Lioy PJ. Environmental copper: its dynamics and human exposure issues. J Toxicol Environ Health B Crit Rev. 2001;4(4):341–94. doi:10.1080/109374001753146207.PubMedCrossRef

18.

WHO. Copper. Copper in drinking-water. Geneva: World Health Organization; 2004. p. 1–23.

19.••

Shen XL, Yu JH, Zhang DF, Xie JX, Jiang H. Positive relationship between mortality from Alzheimer’s disease and soil metal concentration in Mainland China. J Alzheimers Dis. 2014;42(3):893–900. doi:10.3233/JAD-140153. This article provides data about the impact of metal in the soil and mortality for Alzheimer’s disease in mainland China.PubMed

20.

Narasaki M. Laboratory and histological similarities between Wilson’s disease and rats with copper toxicity. Acta Med Okayama. 1980;34(2):81–90.PubMed

21.

Leiva J, Palestini M, Infante C, Goldschmidt A, Motles E. Copper suppresses hippocampus LTP in the rat, but does not alter learning or memory in the morris water maze. Brain Res. 2009;1256:69–75. doi:10.1016/j.brainres.2008.12.041.PubMedCrossRef

22.

Ozcelik D, Uzun H. Copper intoxication; antioxidant defenses and oxidative damage in rat brain. Biol Trace Elem Res. 2009;127(1):45–52. doi:10.1007/s12011-008-8219-3.PubMedCrossRef

23.

Halatek T, Lutz P, Krajnow A, Stetkiewicz J, Domeradzka K, Swiercz R, et al. Assessment of neurobehavioral and biochemical effects in rats exposed to copper smelter dusts. J Environ Sci Health, Part A: Tox Hazard Subst Environ Eng. 2011;46(3):230–41. doi:10.1080/10934529.2011.535407.CrossRef

24.

Mao X, Ye J, Zhou S, Pi R, Dou J, Zang L, et al. The effects of chronic copper exposure on the amyloid protein metabolisim associated genes’ expression in chronic cerebral hypoperfused rats. Neurosci Lett. 2012;518(1):14–8. doi:10.1016/j.neulet.2012.04.030.PubMedCrossRef

25.

An L, Liu S, Yang Z, Zhang T. Cognitive impairment in rats induced by nano-CuO and its possible mechanisms. Toxicol Lett. 2012;213(2):220–7. doi:10.1016/j.toxlet.2012.07.007.PubMedCrossRef

26.

Arcaya JL, Tejeda CM, Salazar U, Silva EJ, Urdaneta K, Varela K. Copper intoxication decreases lifespan and induces neurologic alterations in Drosophila melanogaster. Investig Clin. 2013;54(1):47–57.

27.••

Singh I, Sagare AP, Coma M, Perlmutter D, Gelein R, Bell RD, et al. Low levels of copper disrupt brain amyloid-beta homeostasis by altering its production and clearance. Proc Natl Acad Sci U S A. 2013;110(36):14771–6. doi:10.1073/pnas.1302212110. This article presents data about the non-ceruloplasmin copper causative association with Alzheimer’s disease.PubMedCentralPubMedCrossRef

28.

Pal A, Badyal RK, Vasishta RK, Attri SV, Thapa BR, Prasad R. Biochemical, histological, and memory impairment effects of chronic copper toxicity: a model for non-Wilsonian brain copper toxicosis in Wistar rat. Biol Trace Elem Res. 2013;153(1–3):257–68. doi:10.1007/s12011-013-9665-0.PubMedCrossRef

29.

Pal A, Vasishta R, Prasad R. Hepatic and hippocampus iron status is not altered in response to increased serum ceruloplasmin and serum “free” copper in Wistar rat model for non-Wilsonian brain copper toxicosis. Biol Trace Elem Res. 2013;154(3):403–11. doi:10.1007/s12011-013-9753-1.PubMedCrossRef

30.

Arnal N, Dominici L, de Tacconi MJ, Marra CA. Copper-induced alterations in rat brain depends on route of overload and basal copper levels. Nutrition. 2014;30(1):96–106. doi:10.1016/j.nut.2013.06.009.PubMedCrossRef

31.

Ma Q, Ying M, Sui X, Zhang H, Huang H, Yang L, et al. Chronic copper exposure causes spatial memory impairment, selective loss of hippocampal synaptic proteins, and activation of PKR/eIF2alpha pathway in Mice. J Alzheimers Dis. 2015;43(4):1413–27. doi:10.3233/JAD-140216.PubMed

32.

Sparks DL, Schreurs BG. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2003;100(19):11065–9. doi:10.1073/pnas.1832769100.PubMedCentralPubMedCrossRef

33.

Sparks DL, Friedland R, Petanceska S, Schreurs BG, Shi J, Perry G, et al. Trace copper levels in the drinking water, but not zinc or aluminum influence CNS Alzheimer-like pathology. J Nutr Health Aging. 2006;10(4):247–54.PubMedCentralPubMed

34.

Lu J, Zheng YL, Wu DM, Sun DX, Shan Q, Fan SH. Trace amounts of copper induce neurotoxicity in the cholesterol-fed mice through apoptosis. FEBS Lett. 2006;580(28–29):6730–40. doi:10.1016/j.febslet.2006.10.072.PubMedCrossRef

35.

Arnal N, Castillo O, de Alaniz MJ, Marra CA. Effects of copper and/or cholesterol overload on mitochondrial function in a rat model of incipient neurodegeneration. Int J Alzheimers Dis. 2013;2013:645379. doi:10.1155/2013/645379.PubMedCentralPubMed

36.

Arnal N, Morel GR, de Alaniz MJ, Castillo O, Marra CA. Role of copper and cholesterol association in the neurodegenerative process. Int J Alzheimers Dis. 2013;2013:414817. doi:10.1155/2013/414817.PubMedCentralPubMed

37.••

Squitti R, Simonelli I, Ventriglia M, Siotto M, Pasqualetti P, Rembach A, et al. Meta-analysis of serum non-ceruloplasmin copper in Alzheimer’s disease. J Alzheimers Dis: JAD. 2014;38(4):809–22. doi:10.3233/JAD-131247. This article presents comprehensive data about the concentrations of copper fractions in serum of Alzheimer’s disease and healthy controls.PubMed

38.••

Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. Lancet Neurol. 2015;14(1):103–13. doi:10.1016/S1474-4422(14)70190-5. This review updates recent evidence of copper involvement in neurological disorders.PubMedCrossRef

39.

Bucossi S, Polimanti R, Ventriglia M, Mariani S, Siotto M, Ursini F, et al. Intronic rs2147363 variant in ATP7B transcription factor-binding site associated with Alzheimer’s disease. J Alzheimers Dis: JAD. 2013;37(2):453–9. doi:10.3233/JAD-130431.PubMed

40.

Bucossi S, Polimanti R, Mariani S, Ventriglia M, Bonvicini C, Migliore S, et al. Association of K832R and R952K SNPs of Wilson’s disease gene with Alzheimer’s disease. J Alzheimers Dis. 2012;29(4):913–9. doi:10.3233/JAD-2012-111997.PubMed

41.••

Squitti R, Polimanti R, Bucossi S, Ventriglia M, Mariani S, Manfellotto D, et al. Linkage disequilibrium and haplotype analysis of the ATP7B gene in Alzheimer’s disease. Rejuvenation Res. 2013;16(1):3–10. doi:10.1089/rej.2012.1357. This article provides data about ATP7B genetic association with Alzheimer’s disease.PubMedCentralPubMedCrossRef

42.

Liu HP, Lin WY, Wang WF, Tsai CH, Wu WC, Chiou MT, et al. Genetic variability in copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with Alzheimer’s disease in a Chinese population. J Biol Regul Homeost Agents. 2013;27(2):319–27.PubMed

43.

Squitti R, Lupoi D, Pasqualetti P, Dal Forno G, Vernieri F, Chiovenda P, et al. Elevation of serum copper levels in Alzheimer’s disease. Neurology. 2002;59(8):1153–61.PubMedCrossRef

44.

Squitti R, Pasqualetti P, Cassetta E, Dal Forno G, Cesaretti S, Pedace F, et al. Elevation of serum copper levels discriminates Alzheimer’s disease from vascular dementia. Neurology. 2003;60(12):2013–4.PubMedCrossRef

45.

Squitti R, Bressi F, Pasqualetti P, Bonomini C, Ghidoni R, Binetti G, et al. Longitudinal prognostic value of serum “free” copper in patients with Alzheimer disease. Neurology. 2009;72(1):50–5. doi:10.1212/01.wnl.0000338568.28960.3f.PubMedCrossRef

46.

Squitti R, Ghidoni R, Scrascia F, Benussi L, Panetta V, Pasqualetti P, et al. Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals. J Alzheimers Dis: JAD. 2011;23(2):239–48. doi:10.3233/JAD-2010-101098.PubMed

47.

Squitti R, Pasqualetti P, Polimanti R, Salustri C, Moffa F, Cassetta E, et al. Metal-score as a potential non-invasive diagnostic test for Alzheimer’s disease. Curr Alzheimers Res. 2013;10(2):191–8.CrossRef

48.••

Squitti R, Ghidoni R, Siotto M, Ventriglia M, Benussi L, Paterlini A, et al. Value of serum non-ceruloplasmin copper for prediction of MCI conversion to ad. Ann Neurol. 2014;75(4):574–80. doi:10.1002/ana.24136. This article presents data about the predictive value of Non-ceruloplasmin copper in the rate of conversion to full AD in a cohort Mild Cognitive Impairment subjects followed up for 6 years.PubMedCrossRef

49.•

Squitti R, Polimanti R. Copper hypothesis in the missing hereditability of sporadic Alzheimer’s disease: ATP7B gene as potential harbor of rare variants. J Alzheimers Dis. 2012;29(3):493–501. doi:10.3233/JAD-2011-111991. This review discusses ATP7B allele variants association with Alzheimer’s disease which can account for some ‘missing’ heritability of the disease.PubMed

50.

Bucossi S, Ventriglia M, Panetta V, Salustri C, Pasqualetti P, Mariani S, et al. Copper in Alzheimer’s disease: a meta-analysis of serum, plasma and cerebrospinal studies. J J Alzheimers Dis. 2011;24(1):175–85. doi:10.3233/JAD-2010-101473. Corrected and republished in: J Alzheimers Dis. 2012;30(4):981–4.

51.

Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM. Iron, zinc and copper in the Alzheimer’s disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol. 2011;94(3):296–306. doi:10.1016/j.pneurobio.2011.05.001.PubMedCentralPubMedCrossRef

52.

Schrag M, Mueller C, Zabel M, Crofton A, Kirsch WM, Ghribi O, et al. Oxidative stress in blood in Alzheimer’s disease and mild cognitive impairment: a meta-analysis. Neurobiol Dis. 2013;59:100–10. doi:10.1016/j.nbd.2013.07.005.PubMedCrossRef

53.••

James SA, Volitakis I, Adlard PA, Duce JA, Masters CL, Cherny RA, et al. Elevated labile Cu is associated with oxidative pathology in Alzheimer disease. Free Radic Biol Med. 2012;52(2):298–302. doi:10.1016/j.freeradbiomed.2011.10.446. This article provides data of copper distribution in brain samples of Alzheimer’s disease.PubMedCrossRef

54.

Salustri C, Barbati G, Ghidoni R, Quintiliani L, Ciappina S, Binetti G, et al. Is cognitive function linked to serum free copper levels? A cohort study in a normal population. Clin Neurophysiol: Off J Int Fed Clin Neurophysiol. 2010;121(4):502–7. doi:10.1016/j.clinph.2009.11.090.CrossRef

55.

Scheinberg IH, Sternlieb I. Wilson disease and idiopathic copper toxicosis. Am J Clin Nutr. 1996;63(5):842S–5.PubMed

56.

Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology. 2005;41(3):668–70. doi:10.1002/hep.20601.PubMedCrossRef

57.

Wenisch E, De Tassigny A, Trocello JM, Beretti J, Girardot-Tinant N, Woimant F. Cognitive profile in Wilson’s disease: a case series of 31 patients. Rev Neurol. 2013;169(12):944–9. doi:10.1016/j.neurol.2013.06.002.PubMedCrossRef

58.

Yu J, Luo X, Xu H, Ma Q, Yuan J, Li X et al. Identification of the key molecules involved in chronic copper exposure-aggravated memory impairment in transgenic mice of Alzheimer’s disease using proteomic analysis. J Alzheimers Dis. 2014.

59.

Kivipelto M, Mangialasche F. Alzheimer disease: to what extent can Alzheimer disease be prevented? Nat Rev Neurol. 2014;10(10):552–3.PubMedCrossRef

60.

Exalto LG, Quesenberry CP, Barnes D, Kivipelto M, Biessels GJ, Whitmer RA. Midlife risk score for the prediction of dementia four decades later. Alzheimers Dement. 2014;10(5):562–70.PubMedCrossRef

61.

Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10(9):819–28. doi:10.1016/S1474-4422(11)70072-2.PubMedCentralPubMedCrossRef

62.

Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M, et al. Advances in the prevention of Alzheimer’s disease and dementia. J Intern Med. 2014;275(3):229–50.PubMedCentralPubMedCrossRef

63.

Kivipelto M, Solomon A, Ahtiluoto S, Ngandu T, Lehtisalo J, Antikainen R, et al. The finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER): study design and progress. Alzheimers Dement: J Alzheimers Assoc. 2013;9(6):657–65.CrossRef

64.

Brewer GJ, Yuzbasiyan-Gurkan V, Dick R, Wang Y, Johnson V. Does a vegetarian diet control Wilson’s disease? J Am Coll Nutr. 1993;12(5):527–30.PubMedCrossRef

65.

Weiss KH, Stremmel W. Clinical considerations for an effective medical therapy in Wilson’s disease. Ann N Y Acad Sci. 2014;1315:81–5. doi:10.1111/nyas.12437.PubMedCrossRef

66.•

Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008;7(9):779–86. doi:10.1016/S1474-4422(08)70167-4. This article presents data about a phase II clinical trial with the modulating copper agent PBT2 in Alzheimer’s disease.PubMedCrossRef

67.•

Brewer GJ. Copper excess, zinc deficiency, and cognition loss in Alzheimer’s disease. Biofactors. 2012;38(2):107–13. doi:10.1002/biof.1005. This article presents data about a phase II clinical trial with zinc therapy in Alzheimer’s disease.PubMedCrossRef

68.

Brewer GJ, Askari F, Dick RB, Sitterly J, Fink JK, Carlson M, et al. Treatment of Wilson’s disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res: J Lab Clin Med. 2009;154(2):70–7. doi:10.1016/j.trsl.2009.05.002.CrossRef

69.

Squitti R. Copper subtype of Alzheimer’s disease (AD): meta-analyses, genetic studies and predictive value of non-ceruloplasmim copper in mild cognitive impairment conversion to full AD. J Trace Elem Med Biol: Organ Soc Mineral Trace Elem. 2014;28(4):482–5.CrossRef

70.

Bica L, Liddell JR, Donnelly PS, Duncan C, Caragounis A, Volitakis I, et al. Neuroprotective copper bis(thiosemicarbazonato) complexes promote neurite elongation. PLoS One. 2014;9(2):e90070.PubMedCentralPubMedCrossRef

71.

Pal A, Prasad R. An overview of various mammalian models to study chronic copper intoxication associated Alzheimer’s disease like pathology. Biometals. 2014;12:2014. doi:10.1007/s10534-014-9799-3.

72.

WHO. Copper. Trace elements in human nutrition and health. Geneva: World Health Organization; 1996. p. 123–43.

Titel: The Role of Copper in Human Diet and Risk of Dementia
verfasst von: Rosanna Squitti
Franca Tecchio
Mariacarla Ventriglia
Publikationsdatum: 01.06.2015
Verlag: Springer US
Erschienen in: Current Nutrition Reports / Ausgabe 2/2015
Elektronische ISSN: 2161-3311
DOI: https://doi.org/10.1007/s13668-015-0121-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Let Food Be Thy Medicine: Diet, Nutrition, and Biomarkers’ Risk of Alzheimer’s Disease

Combined Effects of Diet and Exercise or Diet Alone to Improve Physical Function in Community-Dwelling Older Adults: A Systematic Review of the Literature

Caloric Restriction for Treatment of Geriatric Obesity: Do the Benefits Outweigh the Risks?

Over-intake, not White Rice per se, is to Blame in Type-2 Diabetes

Vitamin D and Age-Related Health Outcomes: Movement, Mood, and Memory